As suggested by Cruz-Gill and colleagues [57], the inhibitory effect of miR-19b-1 on ACSL1, ACSL4 and SCD1 in colorectal carcinoma could be exploited as a therapeutic strategy. Here, ACSL1 is linked to colorectal carcinoma.